Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

Abemaciclib, a selective inhibitor of cyclin‐dependent kinases 4 and 6, is metabolized mainly by cytochrome P450 (CYP)3A4. Clinical studies were performed to assess the impact of strong inhibitor (clarithromycin) and inducer (rifampin) on the exposure of abemaciclib and active metabolites. A physiol...

Descripción completa

Detalles Bibliográficos
Autores principales: Posada, Maria M., Morse, Bridget L., Turner, P. Kellie, Kulanthaivel, Palaniappan, Hall, Stephen D., Dickinson, Gemma L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318171/
https://www.ncbi.nlm.nih.gov/pubmed/32080863
http://dx.doi.org/10.1002/jcph.1584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318171/
https://www.ncbi.nlm.nih.gov/pubmed/32080863
http://dx.doi.org/10.1002/jcph.1584

Ejemplares similares